CORBEVAX shot approved for 18 yrs and above jabbed with Covaxin, Covishield

The Central government has approved Biological Ersquos Corbevax for restricted use in an emergency as a heterologous booster dose official sources confirmed on WednesdayOn Tuesday ANI had reported that Corbevax booster for heterologous first has been approved by the CentreLast month the National Technical Advisory Group on Immunisation NTAGI recommended Biological Ersquos CORBEVAX as a heterologous booster for adults above 18 yrs oldOn June 4 this year Biological E Limited BE a Hyderabadbased pharmaceutical and vaccines company announced that its CORBEVAX COVID19 vaccine has been approved by the Drug Controller General of India DCGI as a heterologous booster dose after 6 months of administration of primary jabs of Covaxin or Covishield vaccines for restricted use in the emergency situation for the individuals aged 18 years and aboveldquoBErsquos CORBEVAX is the first such vaccine in India to be approved as a heterologous COVID19 booster Recently BE has furnished its clinical trials data to the DCGI who after a detailed evaluation and deliberations with the Subject Experts Committee granted their approval for administering the Corbevax vaccine as a heterologous booster dose to people who have already taken two doses of either Covishield or Covaxinrdquo an official statement from BE readldquoBErsquos clinical trial data showed that Corbevax booster dose provided significant enhancement in immune response and excellent safety profile required for an effective boosterrdquo it addedMahima Datla Managing Director Biological E Limited said ldquoWe are very happy with this approval which will address the need for COVID19 booster doses in India We have crossed yetanother milestone in our COVID19 vaccination journey This approval reflects that once again sustained worldclass safety standards and high immunogenicity of CorbevaxrdquoldquoBE has conducted a multicentre Phase III placebocontrolled heterologous booster clinical trial in 416 subjects from 18 to 80 years of age who were previously vaccinated with two doses of either COVISHIELD or COVAXIN at least 6 months prior to the administration of Corbevax as a booster doserdquo the statement read furtherldquoThe booster dose of Corbevax increased the neutralizing antibody titers in the Covishield and Covaxin groups significantly when compared to the placebordquo it addedSo far Indiarsquos Cumulative COVID19 vaccination Coverage has exceeded 20703 Crore 2070371204 till 7 am on August 10This story has been sourced from a third party syndicated feed agencies Midday accepts no responsibility or liability for its dependability trustworthiness reliability and data of the text Midday managementmiddaycom reserves the sole right to alter delete or remove without notice the content in its absolute discretion for any reason whatsoever